Ferring Pharmaceuticals has launched testosterone replacement therapy Testavan in the UK.

Testavan is a topical gel with a patented formulation, designed to restore testosterone levels to a normal range in adult males with hypogonadism.

Symptoms of the condition can include decreased libido, erectile dysfunction, fatigue, loss of muscle mass, mood depression, osteoporosis and regression of secondary sexual characteristics.

In Phase III trials, men treated with Testavan achieved normalised testosterone levels by month three, with improvements in quality of life and fatigue scores over three months, and early and sustained increase in erectile function score at one and three months, Ferring noted.

“Low testosterone is a real concern for many men, affecting their quality of life and sexual function. It can also be associated with comorbidities including cardiovascular disease, diabetes, depression, poor bone health and rheumatoid arthritis,” noted Professor Mike Kirby, University of Hertfordshire and The Prostate Centre, London.

“Testavan is an important new treatment option for men who are diagnosed with hypogonadism.”